Suppr超能文献

弥散加权磁共振成像衍生的表观扩散系数可预测原发性中枢神经系统淋巴瘤的临床结局。

Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.

机构信息

Department of Radiology, Neuroradiology Section, University of California San Francisco, San Francisco, California 94117, USA.

出版信息

AJNR Am J Neuroradiol. 2010 Jan;31(1):60-6. doi: 10.3174/ajnr.A1750. Epub 2009 Sep 3.

Abstract

BACKGROUND AND PURPOSE

There is evidence that increased tumor cellular density within diagnostic specimens of primary central nervous system lymphoma (PCNSL) may have significant prognostic implications. Because cellular density may influence measurements of apparent diffusion coefficient (ADC) by using diffusion-weighted MR imaging (DWI), we hypothesized that ADC measured from contrast-enhancing regions might correlate with clinical outcome in patients with PCNSL.

MATERIALS AND METHODS

PCNSL tumors from 18 immunocompetent patients, treated uniformly with methotrexate-based chemotherapy, were studied with pretherapeutic DWI. Enhancing lesions were diagnosed by pathologic analysis as high-grade B-cell lymphomas. Regions of interest were placed around all enhancing lesions allowing calculation of mean, 25th percentile (ADC(25%)), and minimum ADC values. Histopathologic tumor cellularity was quantitatively measured in all patients. High and low ADC groups were stratified by the median ADC value of the cohort. The Welch t test assessed differences between groups. The Pearson correlation examined relationships between ADC measurements and tumor cellular density. Single and multivariable survival analysis was performed.

RESULTS

We detected significant intra- and intertumor heterogeneity in ADC measurements. An inverse correlation between cellular density and ADC measurements was observed (P < .05). ADC(25%) measurements less than the median value of 692 (low ADC group) were associated with significantly shorter progression-free and overall survival. Patients with improved clinical outcome were noted to exhibit a significant decrease in ADC measurements following high-dose methotrexate chemotherapy.

CONCLUSIONS

Our study provides evidence that ADC measurements within contrast-enhancing regions of PCNSL tumors may provide noninvasive insight into clinical outcome.

摘要

背景与目的

有证据表明,原发性中枢神经系统淋巴瘤(PCNSL)诊断标本中的肿瘤细胞密度增加可能具有重要的预后意义。由于细胞密度可能会影响使用弥散加权磁共振成像(DWI)测量表观弥散系数(ADC),我们假设从增强区域测量的 ADC 值可能与 PCNSL 患者的临床结局相关。

材料与方法

对 18 例免疫功能正常的接受甲氨蝶呤为基础的化疗的 PCNSL 患者进行了治疗前 DWI 研究。通过病理分析诊断增强病变为高级别 B 细胞淋巴瘤。在所有增强病变周围放置感兴趣区,以计算平均、25%分位数(ADC(25%))和最小 ADC 值。对所有患者进行了定量的组织病理学肿瘤细胞密度测量。通过队列的中位 ADC 值将高和低 ADC 组分层。Welch t 检验评估组间差异。Pearson 相关性检验 ADC 测量值与肿瘤细胞密度之间的关系。进行单变量和多变量生存分析。

结果

我们检测到 ADC 测量值存在显著的肿瘤内和肿瘤间异质性。细胞密度与 ADC 测量值呈负相关(P<0.05)。ADC(25%)测量值低于中位数 692(低 ADC 组)与无进展生存期和总生存期明显缩短相关。临床结局改善的患者在接受大剂量甲氨蝶呤化疗后,ADC 测量值显著下降。

结论

本研究提供的证据表明,PCNSL 肿瘤增强区域的 ADC 测量值可能为临床结局提供非侵入性的见解。

相似文献

引用本文的文献

2
Automated Lesion and Feature Extraction Pipeline for Brain MRIs with Interpretability.
Neuroinformatics. 2025 Jan 9;23(1):2. doi: 10.1007/s12021-024-09708-z.
5
Differentiation between multifocal CNS lymphoma and glioblastoma based on MRI criteria.
Discov Oncol. 2024 Sep 1;15(1):397. doi: 10.1007/s12672-024-01266-9.
6
Advanced diffusion imaging reveals microstructural characteristics of primary CNS lymphoma, allowing differentiation from glioblastoma.
Neurooncol Adv. 2024 Jun 8;6(1):vdae093. doi: 10.1093/noajnl/vdae093. eCollection 2024 Jan-Dec.
7
Primary central nervous system lymphoma: Imaging features and differential diagnosis.
Neuroradiol J. 2024 Dec;37(6):705-722. doi: 10.1177/19714009241252625. Epub 2024 May 4.
9
Pathological and imaging features, treatment, and prognosis of primary intraventricular lymphoma: A review of cases from a single center.
Heliyon. 2024 Mar 10;10(6):e27942. doi: 10.1016/j.heliyon.2024.e27942. eCollection 2024 Mar 30.
10
Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence.
J Neurooncol. 2023 Oct;165(1):171-179. doi: 10.1007/s11060-023-04473-6. Epub 2023 Oct 13.

本文引用的文献

1
Differential gene expression in central nervous system lymphoma.
Blood. 2009 Jan 1;113(1):266-7; author reply 267-8. doi: 10.1182/blood-2008-04-152835.
4
Protein biomarker identification in the CSF of patients with CNS lymphoma.
J Clin Oncol. 2008 Jan 1;26(1):96-105. doi: 10.1200/JCO.2007.12.1053. Epub 2007 Dec 3.
6
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
J Clin Oncol. 2007 Apr 10;25(11):1350-6. doi: 10.1200/JCO.2006.09.7311. Epub 2007 Feb 20.
7
Primary CNS lymphoma.
Nat Clin Pract Neurol. 2007 Jan;3(1):24-35. doi: 10.1038/ncpneuro0395.
9
Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas. A report of four cases with common and uncommon imaging features.
Clin Neurol Neurosurg. 2007 Jan;109(1):92-101. doi: 10.1016/j.clineuro.2006.03.007. Epub 2006 Apr 27.
10
Gene expression and angiotropism in primary CNS lymphoma.
Blood. 2006 May 1;107(9):3716-23. doi: 10.1182/blood-2005-03-0897. Epub 2006 Jan 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验